Literature DB >> 27940601

Binding Sites for Amyloid-β Oligomers and Synaptic Toxicity.

Levi M Smith1, Stephen M Strittmatter1.   

Abstract

In Alzheimer's disease (AD), insoluble and fibrillary amyloid-β (Aβ) peptide accumulates in plaques. However, soluble Aβ oligomers are most potent in creating synaptic dysfunction and loss. Therefore, receptors for Aβ oligomers are hypothesized to be the first step in a neuronal cascade leading to dementia. A number of cell-surface proteins have been described as Aβ binding proteins, and one or more are likely to mediate Aβ oligomer toxicity in AD. Cellular prion protein (PrPC) is a high-affinity Aβ oligomer binding site, and a range of data delineates a signaling pathway leading from Aβ complexation with PrPC to neuronal impairment. Further study of Aβ binding proteins will define the molecular basis of this crucial step in AD pathogenesis.
Copyright © 2017 Cold Spring Harbor Laboratory Press; all rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27940601      PMCID: PMC5411685          DOI: 10.1101/cshperspect.a024075

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Med        ISSN: 2157-1422            Impact factor:   6.915


  112 in total

1.  Amyloid beta oligomers induce impairment of neuronal insulin receptors.

Authors:  Wei-Qin Zhao; Fernanda G De Felice; Sara Fernandez; Hui Chen; Mary P Lambert; Michael J Quon; Grant A Krafft; William L Klein
Journal:  FASEB J       Date:  2007-08-24       Impact factor: 5.191

2.  The cellular prion protein mediates neurotoxic signalling of β-sheet-rich conformers independent of prion replication.

Authors:  Ulrike K Resenberger; Anja Harmeier; Andreas C Woerner; Jessica L Goodman; Veronika Müller; Rajaraman Krishnan; R Martin Vabulas; Hans A Kretzschmar; Susan Lindquist; F Ulrich Hartl; Gerd Multhaup; Konstanze F Winklhofer; Jörg Tatzelt
Journal:  EMBO J       Date:  2011-03-25       Impact factor: 11.598

3.  Activation and functional characterization of the mosaic receptor SorLA/LR11.

Authors:  L Jacobsen; P Madsen; C Jacobsen; M S Nielsen; J Gliemann; C M Petersen
Journal:  J Biol Chem       Date:  2001-04-09       Impact factor: 5.157

4.  Amyloid-β-induced synapse damage is mediated via cross-linkage of cellular prion proteins.

Authors:  Clive Bate; Alun Williams
Journal:  J Biol Chem       Date:  2011-09-07       Impact factor: 5.157

5.  Nerve growth factor receptor is associated with cholinergic neurons of the basal forebrain but not the pontomesencephalon.

Authors:  N J Woolf; E Gould; L L Butcher
Journal:  Neuroscience       Date:  1989       Impact factor: 3.590

6.  Anti-PrPC monoclonal antibody infusion as a novel treatment for cognitive deficits in an Alzheimer's disease model mouse.

Authors:  Erika Chung; Yong Ji; Yanjie Sun; Richard J Kascsak; Regina B Kascsak; Pankaj D Mehta; Stephen M Strittmatter; Thomas Wisniewski
Journal:  BMC Neurosci       Date:  2010-10-14       Impact factor: 3.288

7.  Augmented humoral and anaphylactic responses in Fc gamma RII-deficient mice.

Authors:  T Takai; M Ono; M Hikida; H Ohmori; J V Ravetch
Journal:  Nature       Date:  1996-01-25       Impact factor: 49.962

8.  Early changes in hippocampal Eph receptors precede the onset of memory decline in mouse models of Alzheimer's disease.

Authors:  Ana María Simón; Rakel López de Maturana; Ana Ricobaraza; Luis Escribano; Lucio Schiapparelli; Mar Cuadrado-Tejedor; Alberto Pérez-Mediavilla; Jesús Avila; Joaquín Del Río; Diana Frechilla
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

9.  Peripheral administration of a humanized anti-PrP antibody blocks Alzheimer's disease Aβ synaptotoxicity.

Authors:  Igor Klyubin; Andrew J Nicoll; Azadeh Khalili-Shirazi; Michael Farmer; Stephanie Canning; Alexandra Mably; Jacqueline Linehan; Alexander Brown; Madeleine Wakeling; Sebastian Brandner; Dominic M Walsh; Michael J Rowan; John Collinge
Journal:  J Neurosci       Date:  2014-04-30       Impact factor: 6.167

10.  Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease.

Authors:  Adam C Naj; Gyungah Jun; Gary W Beecham; Li-San Wang; Badri Narayan Vardarajan; Jacqueline Buros; Paul J Gallins; Joseph D Buxbaum; Gail P Jarvik; Paul K Crane; Eric B Larson; Thomas D Bird; Bradley F Boeve; Neill R Graff-Radford; Philip L De Jager; Denis Evans; Julie A Schneider; Minerva M Carrasquillo; Nilufer Ertekin-Taner; Steven G Younkin; Carlos Cruchaga; John S K Kauwe; Petra Nowotny; Patricia Kramer; John Hardy; Matthew J Huentelman; Amanda J Myers; Michael M Barmada; F Yesim Demirci; Clinton T Baldwin; Robert C Green; Ekaterina Rogaeva; Peter St George-Hyslop; Steven E Arnold; Robert Barber; Thomas Beach; Eileen H Bigio; James D Bowen; Adam Boxer; James R Burke; Nigel J Cairns; Chris S Carlson; Regina M Carney; Steven L Carroll; Helena C Chui; David G Clark; Jason Corneveaux; Carl W Cotman; Jeffrey L Cummings; Charles DeCarli; Steven T DeKosky; Ramon Diaz-Arrastia; Malcolm Dick; Dennis W Dickson; William G Ellis; Kelley M Faber; Kenneth B Fallon; Martin R Farlow; Steven Ferris; Matthew P Frosch; Douglas R Galasko; Mary Ganguli; Marla Gearing; Daniel H Geschwind; Bernardino Ghetti; John R Gilbert; Sid Gilman; Bruno Giordani; Jonathan D Glass; John H Growdon; Ronald L Hamilton; Lindy E Harrell; Elizabeth Head; Lawrence S Honig; Christine M Hulette; Bradley T Hyman; Gregory A Jicha; Lee-Way Jin; Nancy Johnson; Jason Karlawish; Anna Karydas; Jeffrey A Kaye; Ronald Kim; Edward H Koo; Neil W Kowall; James J Lah; Allan I Levey; Andrew P Lieberman; Oscar L Lopez; Wendy J Mack; Daniel C Marson; Frank Martiniuk; Deborah C Mash; Eliezer Masliah; Wayne C McCormick; Susan M McCurry; Andrew N McDavid; Ann C McKee; Marsel Mesulam; Bruce L Miller; Carol A Miller; Joshua W Miller; Joseph E Parisi; Daniel P Perl; Elaine Peskind; Ronald C Petersen; Wayne W Poon; Joseph F Quinn; Ruchita A Rajbhandary; Murray Raskind; Barry Reisberg; John M Ringman; Erik D Roberson; Roger N Rosenberg; Mary Sano; Lon S Schneider; William Seeley; Michael L Shelanski; Michael A Slifer; Charles D Smith; Joshua A Sonnen; Salvatore Spina; Robert A Stern; Rudolph E Tanzi; John Q Trojanowski; Juan C Troncoso; Vivianna M Van Deerlin; Harry V Vinters; Jean Paul Vonsattel; Sandra Weintraub; Kathleen A Welsh-Bohmer; Jennifer Williamson; Randall L Woltjer; Laura B Cantwell; Beth A Dombroski; Duane Beekly; Kathryn L Lunetta; Eden R Martin; M Ilyas Kamboh; Andrew J Saykin; Eric M Reiman; David A Bennett; John C Morris; Thomas J Montine; Alison M Goate; Deborah Blacker; Debby W Tsuang; Hakon Hakonarson; Walter A Kukull; Tatiana M Foroud; Jonathan L Haines; Richard Mayeux; Margaret A Pericak-Vance; Lindsay A Farrer; Gerard D Schellenberg
Journal:  Nat Genet       Date:  2011-04-03       Impact factor: 38.330

View more
  31 in total

Review 1.  Cellular prion protein as a receptor for amyloid-β oligomers in Alzheimer's disease.

Authors:  Santiago V Salazar; Stephen M Strittmatter
Journal:  Biochem Biophys Res Commun       Date:  2016-09-14       Impact factor: 3.575

2.  Liquid and Hydrogel Phases of PrPC Linked to Conformation Shifts and Triggered by Alzheimer's Amyloid-β Oligomers.

Authors:  Mikhail A Kostylev; Marcus D Tuttle; Suho Lee; Lauren E Klein; Hideyuki Takahashi; Timothy O Cox; Erik C Gunther; Kurt W Zilm; Stephen M Strittmatter
Journal:  Mol Cell       Date:  2018-10-25       Impact factor: 17.970

3.  PrP-grafted antibodies bind certain amyloid β-protein aggregates, but do not prevent toxicity.

Authors:  David Mengel; Wei Hong; Grant T Corbett; Wen Liu; Alexandra DeSousa; Laura Solforosi; Cheng Fang; Matthew P Frosch; John Collinge; David A Harris; Dominic M Walsh
Journal:  Brain Res       Date:  2018-12-26       Impact factor: 3.252

Review 4.  Microglial memory of early life stress and inflammation: Susceptibility to neurodegeneration in adulthood.

Authors:  Paula Desplats; Ashley M Gutierrez; Marta C Antonelli; Martin G Frasch
Journal:  Neurosci Biobehav Rev       Date:  2019-11-05       Impact factor: 8.989

5.  Conditional Deletion of Prnp Rescues Behavioral and Synaptic Deficits after Disease Onset in Transgenic Alzheimer's Disease.

Authors:  Santiago V Salazar; Christopher Gallardo; Adam C Kaufman; Charlotte S Herber; Laura T Haas; Sophie Robinson; Jean C Manson; Michael K Lee; Stephen M Strittmatter
Journal:  J Neurosci       Date:  2017-08-21       Impact factor: 6.167

6.  Systematic and standardized comparison of reported amyloid-β receptors for sufficiency, affinity, and Alzheimer's disease relevance.

Authors:  Levi M Smith; Mikhail A Kostylev; Suho Lee; Stephen M Strittmatter
Journal:  J Biol Chem       Date:  2019-02-20       Impact factor: 5.157

7.  Rescue of Transgenic Alzheimer's Pathophysiology by Polymeric Cellular Prion Protein Antagonists.

Authors:  Erik C Gunther; Levi M Smith; Mikhail A Kostylev; Timothy O Cox; Adam C Kaufman; Suho Lee; Ewa Folta-Stogniew; George D Maynard; Ji Won Um; Massimiliano Stagi; Jacqueline K Heiss; Austin Stoner; Geoff P Noble; Hideyuki Takahashi; Laura T Haas; John S Schneekloth; Janie Merkel; Christopher Teran; Zahra K Naderi; Surachai Supattapone; Stephen M Strittmatter
Journal:  Cell Rep       Date:  2019-01-02       Impact factor: 9.423

Review 8.  PET imaging of synaptic density: A new tool for investigation of neuropsychiatric diseases.

Authors:  Zhengxin Cai; Songye Li; David Matuskey; Nabeel Nabulsi; Yiyun Huang
Journal:  Neurosci Lett       Date:  2018-07-31       Impact factor: 3.046

Review 9.  A mechanistic hypothesis for the impairment of synaptic plasticity by soluble Aβ oligomers from Alzheimer's brain.

Authors:  Shaomin Li; Dennis J Selkoe
Journal:  J Neurochem       Date:  2020-04-05       Impact factor: 5.372

Review 10.  Synaptotoxic Signaling by Amyloid Beta Oligomers in Alzheimer's Disease Through Prion Protein and mGluR5.

Authors:  A Harrison Brody; Stephen M Strittmatter
Journal:  Adv Pharmacol       Date:  2017-10-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.